PHTHALATE EXPOSURE AND BREAST-CANCER RISK ACCORDING TO PPARy AND PPARGC1B GENOTYPES

Gabriela A. Martínez-Nava, National Institute of Public Health, Cuernavaca, Morelos, Mexico

Lizbeth López-Carrillo, National Institute of Public Health, Cuernavaca, Morelos, Mexico

Mariano E. Cebrián-García, Department of Toxicology, Research and Advanced Studies Center of the National Polytechnic Institute of Mexico, Mexico City, Mexico

Antonia M. Calafat, Department of Toxicology, Research and Advanced Studies Center of the National Polytechnic Institute of Mexico, Mexico City, Mexico

Vicente Madrid-Marina, National Institute of Public Health, Cuernavaca, Morelos, Mexico

Raúl U. Hernández-Ramirez National Institute of Public Health, Cuernavaca, Morelos, Mexico Ana I. Burguete-García, National Institute of Public Health, Cuernavaca, Morelos, Mexico

Background and Aims: Some phthalic acid diesters (phthalates) have recently been associated with breast cancer (BC). In this study we evaluated if that association is modified according to *PPARy* and *PPARGC1B* genotypes.

Methods: 208 BC cases were age-matched with 220 population controls from the north of Mexico. Urine concentrations of nine phthalate metabolites were determined by isotope dilution/high-performance liquid chromatography and mass spectrometry. Genotyping of variant *Pro12Ala* (rs1801281) of the *PPARy* gene and variants *Ala203Pro* (rs7732671) and *Val279lle* (rs17572019) of the *PPARGC1B* gene were carried out by traditional PCR with TaqMan probes.

Results: The three polymorphisms under study were in Hardy-Weinberg equilibrium, with a minor allele frequency of 0.11, 0.14, and 0.14 for the *Pro12Ala*, *Ala203Pro*, and *Val279Ile* variants respectively. Only the association between the higher levels of urinary mono-(2-ethylhexyl) phthalate (MEHP) concentration with BC was modified after the stratification by the *PPARy* gene *Pro12Ala* polymorphism alleles (for G carriers: OR=0.59 Cl95%=0.25-1.39; for C carriers: OR=1.50 Cl95%=1.08-2.08); and the association between the mono-iso-butyl phthalate (MiBP) with BC in women with higher urinary concentrations was modified after the stratification by the *PPARGC1B* gene *Ala203Pro* polymorphism alleles (for C carriers OR=1.12 Cl95%=0.55-2.27; for G carriers OR=0.67 Cl95%=0.44-1.01).

Conclusions: Our results suggest the presence of a gene-environment interaction influencing BC risk that could be determined by the magnitude of exposure.

Keywords: breast cancer, phthalates, urinary metabolites, PPARy, PPARGC1B, gene-environment interaction.